• Designing a Learning and Performance Program in Tissue and Organ Banking

    13 April, 2017 David Hofstetter, Manager, Learning and Development, New England Organ Bank

    Keeping up with the changes and the training in tissue and organ banking is an ongoing process. We know what works well and what doesn't. We know with a field-based staff that classroom training is difficult to pull off when trying to coordinate everyone's schedules and of course working around the case load. What we have found is that online learning or on-demand learning does work. This allows all of the staff to access training when and where they need it. We currently offer the following typ

    Full story
  • The Changing Face of Biobanks

    13 April, 2017 Jeanene Swanson

    Biobanking is changing rapidly, and it's in no small part due to the demands of systems biology. While small, university-centered banks have existed for decades, large-scale biobanks - whether tissue repositories or population databases - have recently been implemented all across the world. Many are also adding clinical annotation, genetic data, and increasingly genomic, proteomic, and other 'omics information. Population-wide biobanks exist in Iceland, the UK, Sweden, Canada, Estonia, Latvia, S

    Full story
  • Blood & Biologics Lifeline - Health Canada Draft Guidance Issued in March

    Diane Whitworth, Principal Research Consultant, DRW Research & Information Services, LLC

    With Health Canada's recent publication of its draft guidance entitled, "Information and Submission Requirements for Subsequent Entry Biologics (SEBs)," the agency has initiated its plan to introduce a comprehensive regulatory, legal and scientific framework to approve biologic products that are similar to already approved biologics upon patent expiration. These products, also referred to as biosimilars by the agency, have posed a regulatory challenge for government agencies worldwide. The Europ

    Full story
  • Blood Substitute's Effectiveness and Safety Addressed In Large Clinical Trial

    13 April, 2017 MasterControl

    A predicted shortfall of over 4 million units of blood worldwide is driving the need to develop an alternative to red blood cells.Academic and industry researchers participated in a Phase III multi-center clinical trial and found that use of a blood substitute was relatively safe in patients under 80 years old who have a moderate need for transfusion, up to the equivalent of three units of regular blood.Published in the June edition of the Journal of Trauma® this study is the first

    Full story
  • Conferees Seek Paths to Improving Blood Center IT Systems

    13 April, 2017 MasterControl

    Blood community professionals and vendors met with officials from the Food and Drug Administration in a first-of-its-kind conference examining the impact of federal regulations on the development of donor and transfusion information technology (IT) systems.

    Full story
  • Blood Center Accreditation by CAP Article

    MasterControl

    FDA-regulated blood centers, clinical laboratories, and related establishments are under tremendous pressure to maintain the highest standards for blood and tissue quality.

    Full story
  • Blood Center Accreditation by CAP Can Boost FDA Compliance

    MasterControl

    FDA-regulated blood centers, clinical laboratories, and related establishments are under tremendous pressure to maintain the highest standards for blood and tissue quality.

    Full story
  • Tracking Blood Electronically Article

    13 April, 2017 Jerry D. Holcombe

    Blood centers have been using reliable and easy-to-scan barcodes to positively identify and track blood products for decades. Radio Frequency Identification (RFID) technology has been widely used in other industries with myriad applications for years. Marrying the two technologies for transfusion medicine can make it possible to "read" containers of blood simultaneously, reduce costs, streamline operations, and ultimately prevent mismatched blood at the point of transfusion. The addition of RFID

    Full story
  • Blood & Biologics Article - Preparing For EU Assessment

    13 April, 2017 MasterControl

    By Becky SeeDiscusses how a U.S. blood center should prepare for an EU inspection.A safe and adequate blood supply is essential to the practice of modern medicine. New advances, particularly in the area of automation, have enhanced both safety and blood availability on an international scale.  Sovereign countries formerly looked to their own citizens for their blood plasma needs; today, plasma is an international commodity and as such, its collection centers are assessed by European a

    Full story
  • U.S. Biovigilance Network: Hemovigilance System

    13 April, 2017 Barbee Whitaker, Ph.D. AABB, Director, Data and Special Programs

    AABB, formerly the American Association of Blood Banks, and the Department of Health and Human Services have partnered to develop the U.S. Biovigilance Network. This network will, for the first time on a nationwide basis, collect and analyze data to identify trends and recommend best practices to reduce adverse reactions and incidents associated with blood transfusion and related biological therapies. Ultimately, the analyses of this data will enhance patient safety, make better use of blood and

    Full story
  • AABB Abstract Submission: Everything You Wanted to Know but Didn't Ask

    MasterControl

    The AABB Annual Meeting and TXPO, slated for October 24 - 27 in New Orleans, hosts many educational activities. Among these is the Abstract Poster session, an opportunity to share your research with others and possibly obtain preliminary publication for grant and funding purposes.

    Full story
  • 21 CFR Part 601 and Vaccine Approval

    13 April, 2017 MasterControl

    21 CFR Part 601 and Accelerated Vaccine Approval: Five Things You Need to Know21 CFR Part 601 Provides Basis for Accelerated Vaccine Approval

    Full story
  • Biologic-Device Combination Products: Jurisdiction

    Joyce L. Frey-Vasconcells, Executive Director, PharmaNet Consulting, PharmaNet Development Group, Pharmanet.com

    More and more companies are developing combination products for many life-threatening and unmet medical needs. One area that holds much promise is the development of tissue engineered products which contain living cells or tissues combined with a device. As with any novel technology, questions regarding what the requirements will be by the regulators to obtain market approval is always an issue. This has been a changing dynamic in other parts of the world but the Food and Drug Administration

    Full story
  • Why Baldrige Works

    15 February, 2011 Rose Almon-Martin, V.P. Performance Excellence, MEDRAD, Warrendale, Pa.

    There's no doubt that the Baldrige Criteria drive excellent performance. Of course, the perennial question for any improvement approach is "What's the return on my investment?" Cargill, a $107 billion company that produces and markets food, agricultural, financial and industrial products and services, says Baldrige is a huge return on investment. Their divisions that use the Criteria achieve 130 percent of their earnings targets versus divisions not using the Criteria, who achieve about 82 perce

    Full story
  • Tips for Avoiding Internal and External Supplier Problems

    Seth Mailhot, Lead, FDA Practice, Nixon Peabody LLP

    The signing of the historic healthcare reform legislation will have a significant impact on both the medical device and pharmaceutical industries. A significant increase in the number of individuals carrying health insurance will translate into a greater demand for medical devices and pharmaceuticals. While this will improve profitability for many companies, it will present challenges to manufacturing and quality managers tasked with finding ways to quickly increase production.

    Full story
  • Avoiding the CAPA Calamity

    9 February, 2017 Ken Peterson, Director Quality Services, MasterControl, Inc.

    Anyone working in quality management is familiar with references to "Death by CAPA" or "CAPA Kills." The industry is rife with similar catch phrases. The "truth" is they are not far from the "truth." When my friend from FDA originally coined the expression "death by CAPA," it was with the best of intentions. Her concern was for those who were killing their respective companies with an overabundance of entries into the CAPA system. These employees were doing so in an effort to ensure all tha

    Full story
  • Automating Training Control Processes to Comply with FDA and ISO Requirements

    Brian Curran, SVP, Stategic Marketing & Product Management, MasterControl, Inc.

    FDA regulatory requirements and ISO quality standards mandate companies to execute and document employee training. (21 CFR 211.25 and 820.25) These requirements ensure employees understand how to perform their duties within company and industry guidelines. Well-managed training programs minimize the risk of non-compliance and improve product quality. This article identifies the basis for the requirement and examines the associated challenges for meeting the requirement and the shortcomings that

    Full story
  • Automating Document Control Processes to Comply with FDA and ISO Requirements

    13 April, 2017 Jason Clegg, Marketing Director, MasterControl, Inc.

    The purpose of document control systems is to ensure that manufacturers build products that are safe and reliable. ISO and FDA Current Good Manufacturing Practices (CGMPs) presume that both the process and documentation that directs company processes follows pre-approved methods and that any change to these methods is restricted to authorized personnel and tracked for future review. All FDA-regulated and ISO-certified companies are mandated to have a document change control system.

    Full story
  • How Auditing Supports Supply Chain Management

    6 October, 2010 Dennis R. Arter, FASQ, CQA

    There are four parts of supply-chain management:

    Full story